NKTR 214

Drug Profile

NKTR 214

Alternative Names: NKTR214

Latest Information Update: 14 Nov 2016

Price : $50

At a glance

  • Originator Nektar Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Developer Bristol-Myers Squibb; Nektar Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cytokines
  • Mechanism of Action Immunostimulants; Interleukin-2 receptor beta subunit agonists; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Preclinical Bladder cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma

Most Recent Events

  • 09 Nov 2016 Adverse events, efficacy and immunogenicity data from a phase I trial in Solid tumours released by Nektar Therapeutics
  • 27 Sep 2016 Preclinical trials in Bladder cancer in USA (IV)
  • 27 Sep 2016 Preclinical trials in Colorectal cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top